Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05197322Phase 2Recruiting

NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

Role: collaborator

NCT05080946Early Phase 1Recruiting

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Role: collaborator

NCT06613516Phase 2Withdrawn

Effect of Capivasertib on ctDNA in ER Positive Breast Cancer

Role: collaborator

NCT02279524Phase 2Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

Role: collaborator

All 4 trials loaded